<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108352</url>
  </required_header>
  <id_info>
    <org_study_id>KH902-BRVO-CRP-1.0</org_study_id>
    <nct_id>NCT03108352</nct_id>
  </id_info>
  <brief_title>Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion</brief_title>
  <acronym>BRAVE</acronym>
  <official_title>Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the efficacy and safety of intravitreal injection of&#xD;
      conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion&#xD;
      (BRVO).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>month 6</time_frame>
    <description>Compare mean changes in Best Corrected Visual Acuity (BCVA) from baseline between the Conbercept ophthalmic injection treatment group (treatment group) and the control group at month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>month 3 and month 12</time_frame>
    <description>1&gt;o evaluate mean changes in BCVA from baseline of the treatment group and the control group at month 3 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Retinal Thickness</measure>
    <time_frame>month 3, month 6 and month 12</time_frame>
    <description>To evaluate mean changes in Central Retinal Thickness (CRT) from baseline of the treatment group and the control group at month 3, 6 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resue treament</measure>
    <time_frame>month 6 and month 12</time_frame>
    <description>To evaluate the number of subjects who received laser rescue treatment of the treatment group and the control group at month 6 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related the systemic and ocular safely as assessed</measure>
    <time_frame>up to 12.5 months</time_frame>
    <description>To evaluate the systemic and ocular safety of the treatment group and the control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of BCVA changes</measure>
    <time_frame>month 3, month 6 and month 12</time_frame>
    <description>To evaluate the distribution of BCVA changes from baseline of the treatment group and the control group at month 3, 6 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean changes in BCVA</measure>
    <time_frame>month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12</time_frame>
    <description>To evaluate mean changes in BCVA from baseline of the treatment group and the control group at every visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in image</measure>
    <time_frame>month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12</time_frame>
    <description>To evaluate the average changes in imaging findings (e.g., CRT and total macular volume) relative to the baseline for treatment group and control group at each follow-up visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenic positive response in the treatment group</measure>
    <time_frame>baseline,month 6, month 12</time_frame>
    <description>Number of participants with Treatment-Ralated positive response to anti-drug antibody（ADA）or neutralizing antibody(Nab) in the treatment group at baseline,6 and 12months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenic positive response in the control group</measure>
    <time_frame>baseline,month 6, month 12</time_frame>
    <description>Number of participants with Treatment-Ralated positive response to anti-drug antibody（ADA）or neutralizing antibody(Nab) in thecontrol group at baseline,6 and 12months.</description>
  </other_outcome>
  <other_outcome>
    <measure>safety analysis of immunogenic positive response</measure>
    <time_frame>month 12</time_frame>
    <description>To analyze the safely of subjects with positive response to ADA or Nab at 12 months after treatment and number of participants with positive respone who develop anticipants immuogenic adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>safety analysis of immunogenic negative response</measure>
    <time_frame>month 12</time_frame>
    <description>To analyze the safely of subjects with negative response to ADA or Nab at 12 months after treatment and number of participants with negative response who develop anticipants immuogenic adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>month 12</time_frame>
    <description>To analyze the BCVA for subjects with positive response to ADA or Nab at 12 months after treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Conbercept ophthalmic injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham/Conbercept ophthalmic injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept ophthalmic injection</intervention_name>
    <arm_group_label>Conbercept ophthalmic injection</arm_group_label>
    <arm_group_label>sham/Conbercept ophthalmic injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham injection</intervention_name>
    <arm_group_label>sham/Conbercept ophthalmic injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have signed informed consent form and agreed to be followed up as per the&#xD;
             trial protocol;&#xD;
&#xD;
          -  Aged ≥ 18 years, male or female;&#xD;
&#xD;
          -  Study eyes must meet all of following requirements:&#xD;
&#xD;
               -  Suffering from macular edema secondary to BRVO that involves the fovea and BRVO&#xD;
                  has been first diagnosed within previous 12 months;&#xD;
&#xD;
               -  Best corrected visual acuity (BCVA) ≥24 and ≤73 letters (Snellen equivalent is&#xD;
                  20/320 - 20/40);&#xD;
&#xD;
               -  Central retinal thickness (CRT) on OCT is ≥300 μm;&#xD;
&#xD;
          -  Without opacities in the refractive media and pupillary miosis that affects fundus&#xD;
             examination.&#xD;
&#xD;
        Note: The eye of interest is determined by the researcher from a medical point of view if&#xD;
        both eyes of the patient meet the inclusion criteria. In principle, the eye with poor&#xD;
        eyesight or thicker central retina should be selected as the eye of interest.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any subject who has any of the following ocular condition:&#xD;
&#xD;
          1. Eye of interest&#xD;
&#xD;
               -  Has active retina and/or iris neovascularization;&#xD;
&#xD;
               -  Has macular epiretinal membranes or vitreous tractions which are considered to&#xD;
                  influence the central visual acuity by the researcher;&#xD;
&#xD;
               -  Has other diseases which are considered to influence the macular functional&#xD;
                  recovery by the researcher, e.g., foveal atrophy, subfoveal hemorrhage, macular&#xD;
                  hard exudates or dense submacular hard exudates;&#xD;
&#xD;
               -  Has a history of any type of retinal detachment;&#xD;
&#xD;
               -  Has non-RVO ocular diseases which are considered to possibly cause macular edema,&#xD;
                  declined visual acuity or retinal neovascularization during the study period by&#xD;
                  the researcher, e.g., wet AMD, diabetic retinopathy, uveitis/other intraocular&#xD;
                  inflammatory diseases, neovascular glaucoma and cystoid macular edema;&#xD;
&#xD;
               -  Is considered to require cataract surgery in the next 12 months by the&#xD;
                  researcher;&#xD;
&#xD;
               -  Has received intravitreal injection of corticosteroids within three months before&#xD;
                  screening, subconjunctival injection of corticosteroids within six months, or&#xD;
                  local treatment with ocular corticosteroids within one month;&#xD;
&#xD;
               -  Has received the following ophthalmic operations: scleral buckling,&#xD;
                  verteporfin-photodynamic therapy (PDT), vitrectomy, radial optic neurotomy/optic&#xD;
                  nerve sheathotomy, glaucoma filtration, parafoveal laser photocoagulation,&#xD;
                  pan-retinal photocoagulation, and macular translocation;&#xD;
&#xD;
               -  Has received YAG laser treatment or any other ophthalmic treatments (including&#xD;
                  cataract surgery, macular grid laser photocoagulation, local retinal&#xD;
                  photocoagulation, and keratoplasty) within three months before screening;&#xD;
&#xD;
               -  Has a BCVA increment by more than 10 alphabets during the screening period (BCVA&#xD;
                  tested within 24 hours before medication at Day 0 versus BCVA at the time of&#xD;
                  screening);&#xD;
&#xD;
               -  Has aphakic eye (excluding pseudophakic) or or posterior lens capsule (except YAG&#xD;
                  laser posterior capsulotomy after intraocular lens implantation);&#xD;
&#xD;
          2. Either eye:&#xD;
&#xD;
               -  Has active periocular or ocular inflammation (e.g., blepharitis, infective&#xD;
                  conjunctivitis, keratitis, scleritis, uveitis, and endophthalmitis);&#xD;
&#xD;
               -  Has previous or existing uncontrollable glaucoma (defined as IOP remaining at ≥&#xD;
                  30 mmHg after anti-glaucoma treatment), or has a cup-to-disc ratio of the eye of&#xD;
                  interest of above 0.8 due to severe glaucoma;&#xD;
&#xD;
               -  Has received intravitreal injection of any anti-VEGF agents (e.g.,ranibizumab,&#xD;
                  bevacizumab, and conbercept) within three months before screening;&#xD;
&#xD;
        Patient with any of the following systemic diseases:&#xD;
&#xD;
          -  Has a history of anaphylaxis and allergy to fluorescein sodium, and of allergy to&#xD;
             protein products for diagnosis or treatment, and is allergic to no less than two drugs&#xD;
             and/or non-drug factors, or suffers from allergic diseases now;&#xD;
&#xD;
          -  Has a history of stroke, has a history of myocardial and/or cerebral infarction(s) and&#xD;
             of transient cerebral ischemia within 6 months before screening, and has active and&#xD;
             disseminated intravascular coagulation and distinct bleeding tendency;&#xD;
&#xD;
          -  Has confirmed systemic immune disease (e.g., ankylosing spondylitis, systemic lupus&#xD;
             erythematosus, and Behcet's disease, rheumatoid arthritis, and scleroderma);&#xD;
&#xD;
          -  Has any uncontrollable clinical problem (e.g., AIDS, active hepatitis, severe mental,&#xD;
             neurological, cardiovascular and respiratory diseases, and malignancies);&#xD;
&#xD;
          -  Hyperpietics with poor blood pressure control (defined as SBP remaining at ≥ 160 mmHg&#xD;
             or DBP remaining ≥ 100 mmHg after antihypertensives therapy);&#xD;
&#xD;
          -  Has a surgical history within one month before screening, and/or has unhealed wounds,&#xD;
             ulcers and fractures at present;&#xD;
&#xD;
          -  Has systemically used corticosteroids (orally, intramuscularly, intravenously) within&#xD;
             6 months before screening;&#xD;
&#xD;
          -  Has received systemic treatment with anti-VEGF agent(s) (e.g., bevacizumab) within 6&#xD;
             months before screening; Patients with any of the following abnormal laboratory tests&#xD;
&#xD;
          -  Those who have hepatic, renal and immunologic dysfunction (this trial specifies that&#xD;
             ALT and AST are twice as high as the ULN of this central laboratory, and that Crea and&#xD;
             BUN are 1.5-fold as high as the ULN of this central laboratory);&#xD;
&#xD;
          -  Those who have coagulation abnormalities (PT is 3 seconds greater than or equal to the&#xD;
             ULN, and APTT is 10 seconds greater than or equal to the ULN); Patients of&#xD;
             childbearing age with any of the following condition&#xD;
&#xD;
          -  Those who do not take effective contraceptive measures at childbearing age; Note: The&#xD;
             following conditions are not included in the exclusion range.&#xD;
&#xD;
               1. Amenorrhea for 12 months under the natural condition, or amenorrhea for 6 months&#xD;
                  under the natural condition and the serum FSH level of &lt; 40 mIU/ml;&#xD;
&#xD;
               2. Six weeks after bilateral ovariectomy with/without hysterectomy;&#xD;
&#xD;
               3. Use of the following one or more acceptable contraceptions:&#xD;
&#xD;
                    -  Sterilization (for males, with bilateral vasoligation and vasectomy)&#xD;
&#xD;
                    -  Hormonal contraception (implantable, patchable, oral)&#xD;
&#xD;
                    -  Intrauterine device and dural barrier method&#xD;
&#xD;
               4. Ability to take reliable contraceptive measures over the study period and hold on&#xD;
                  to 30 days after study drug withdrawal (unacceptable contraceptive methods&#xD;
                  include: periodic continence - according to the calendar and ovulatory phase,&#xD;
                  body thermometry, post-ovulatory method, and coitus interruptus);&#xD;
&#xD;
          -  Pregnant women and breastfeeding mothers (in this trial pregnancy is defined as&#xD;
             positive U-HCG); Others&#xD;
&#xD;
          -  Patient has participated in any drug (not including vitamins and minerals) clinical&#xD;
             trial three months before screening (if the study drug has a long half-life, i.e., its&#xD;
             five half-lives exceed three months, then it is deemed as five half-lives); Any&#xD;
             condition in which the researcher deems necessary to be excluded in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wenbin weni</last_name>
    <phone>86-010-58269152</phone>
    <email>tr_weiwenbin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling WANG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxin LI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital, Capital Medical University</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenbin WEI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei YUAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong LI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eys Hosptial of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoling LIU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Frist Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li QIN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

